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Background: In Belgium, the construction of the national electronic point-of-care information service,
EBMPracticeNet, was initiated in 2011 to optimize quality of care by promoting evidence-based decision-making.
The collaboration of the government, healthcare providers, Evidence-Based Medicine (EBM) partners, and vendors
of Electronic Health Records (EHR) is unique to this project. All Belgian healthcare professionals get free access to
an up-to-date database of validated Belgian and nearly 1,000 international guidelines, incorporated in a portal that
also provides EBM information from sources other than guidelines, including computerized clinical decision support
that is integrated in the EHRs.
The EBMeDS system is the electronic evidence-based decision support system of EBMPracticeNet. The EBMeDS
system covers all clinical areas of diseases and could play a crucial role in response to the emerging challenge
posed by chronic conditions. Diabetes was chosen as the analysis topic of interest. The objective of this study is to
assess the effectiveness of EBMeDS use in improving diabetes care. This objective will be enhanced by a formal
process evaluation to provide crucial information on the feasibility of using the system in daily Belgian family
medicine.
Methods: The study is a cluster-randomized trial with before/after measurements conducted in Belgian family
medicine. Physicians’ practices will be randomly assigned to the intervention or control group in a 1:1 ratio, to
receive either the EBMeDS reminders or to follow the usual care process. Randomization will be performed by a
statistical consultant with an electronic random list generator, anonymously for the researchers. The follow-up
period of the study will be 12 months with interim analysis points at 3, 6 and 9 months. Primary outcome is the
one-year pre- to post-implementation change in HbA1c. Patients will not be informed about the intervention. Data
analysts will be kept blinded to the allocation.
Discussion: The knowledge obtained in this study will be useful for further integration in other Belgian software
packages. Users’ perceptions and process evaluation will provide information for improving the feasibility of the
system.
Trial registration: The trial is registered with the ClinicalTrials.gov registry: NCT01830569.
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Evidence is of no use if it remains buried in the literature
and is not implemented in practice. A first step is the con-
version of evidence from studies into clinical practice
guidelines. Point-of-care decision support systems based
on electronic guidelines have been suggested to success-
fully deliver the knowledge embedded in Evidence-Based
(E-B) guidelines [1,2]. A number of studies have already
shown positive findings for some types of decision support
systems such as drug-dosing systems and computer-based
reminder systems for preventive care services [3,4]. The
evidence is less clear for more complex electronic guide-
line implementation systems [5-9].
In Belgium, the construction of the national electronic
point-of-care information service EBMPracticeNet was ini-
tiated in 2011 to optimize quality of care by promoting
evidence-based decision-making. The National Institute
for Health and Disability Insurance (INAMI-RIZIV) pro-
vides funding for this organization. The collaboration of
the government, healthcare providers, Evidence-Based
Medicine (EBM) partners, and vendors of Electronic
Health Records (EHR) is unique to this project. All Belgian
healthcare professionals get free access to an up-to-date
database of validated Belgian and nearly 1,000 international
guidelines, incorporated in a portal that also provides EBM
information from sources other than guidelines, including
computerized clinical decision support that is integrated in
the EHRs. The link between all the EHRs from different
vendors and a national database held on a single platform
and controlled by all EBM organizations in Belgium is the
strength of EBMPracticeNet [10].
The EBMeDS system is the electronic evidence-based
decision support system of EBMPracticeNet. The EBMeDS
system was developed by Duodecim [11] and will gradually
be integrated in the different Belgian software packages.
EBMeDS is currently being integrated in the software of
HealthOne, one of the Belgian electronic medical record
systems (EMR).
The main distinguishing feature of the EBMeDS system
is its intuitive approach and its platform-independent,
service-oriented architecture, with strong central manage-
ment. This has been recognized as being critically import-
ant for keeping the evidence up-to-date and for
integrating the system in the different software packages
used by all physicians involved in the care processes. In
addition, the involvement of end-users during the imple-
mentation process is a critical feature of its success
[12,13].
The EBMeDS system covers all clinical areas of dis-
eases and could play a crucial role in response to the
emerging challenge posed by chronic conditions such as
hypertension, diabetes, and heart failure, etc. Chronic
conditions increasingly affect the population and could
lead to serious complications and disability in the longterm if not managed appropriately in a proactive
healthcare system. Chronic conditions require collabor-
ation between different healthcare workers, recurrent
visits, adherence to (sometimes overlapping or diver-
ging) care plans and long-term disease and treatment
monitoring [5]. Theoretically, the EBMeDS system has
the potential to deal with these multifactorial dimen-
sions of chronic diseases in ambulatory settings.
As with any health intervention, rigorous testing is
warranted to determine whether the EBMeDS system
could realize improvements in chronic care processes
and, more especially, patient outcomes. Based on the re-
sults of a previous qualitative study in a pilot setting, we
adapted the mode of evidence delivery and the quantity
of reminders of a previous version of the system to pre-
vent reminder fatigue [14].
Diabetes was chosen as the analysis topic of interest.
Type II diabetes mellitus is a highly prevalent disease
and at the moment the leading cause of blindness, renal
dysfunction, non-traumatic limb amputation, and de-
creased life expectancy [15]. Optimal care of diabetes pa-
tients has been difficult to achieve because of the
difficulties in sustaining regular monitoring and atten-
tion to many risk factors over many years [16]. Clear
recommendations on the basis of high levels of evidence
exist to prevent these complications, but there is still a
large gap between recommended care and the care that
patients actually receive [17,18].
The objective of this study is to assess the effectiveness
of EBMeDS use in improving diabetes care as a case
study. This objective will be enhanced by a formal
process evaluation to provide crucial information on the
feasibility of using the system in daily Belgian family
medicine.
Methods
The study is a cluster-randomized trial with before/after
measurements conducted in Belgian family medicine. A
cluster design is necessary to minimize contamination
that might occur if individual patients were randomized.
Randomization will be performed at practice level; the
intervention will happen at physician level; and data will
be analyzed at patient level, in a multilevel analytical ap-
proach. The follow-up period of the study will be
12 months.
Physicians’ practices will be randomly assigned to the
intervention or control group in a 1:1 ratio, to receive ei-
ther the EBMeDS reminders or to follow the usual care
process.
Participants and setting
Physicians eligible to participate in the study are all fam-
ily physicians (739 Dutch-speaking and 891 French-
speaking) using HealthOne (1,630 family physicians).
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met:
1. The physician has integrated HealthOne in his
consultations;
2. The physician uses the functionality of e-prescribing
within HealthOne so that prescribed medication can
be identified from the electronic medical records;
and
3. The physician agrees to be involved in the study.
Patients are included if:
1. They are 18 years or older.
2. They have their electronic medical records
registered with one of the participating family
physicians. Medical records are not centralized in
Belgium. Patients are free to choose any physician,
and can even see several physicians at the same
time. To encourage a patient to have their medical
records held by a single physician, a voluntary
enlisting program was introduced (Global Medical
File) a decade ago. For every enlisted patient, the
general practitioner who keeps their central medical
records receives a registration fee. Enlisted patients
are reimbursed to a larger extent by the health
insurance fund.
3. They are enlisted and have an established diagnosis
of diabetes at the baseline time point of the study
(identified as having: an ICPC code of diabetes; or a
prescription for a diabetes-specific drug; or the
necessary laboratory results to confirm diabetes).
Exclusion criteria are pregnancy and cognitive
impairment.
Interventions
Trial preparation
To ensure that the point-of-care information provided
through the EBMeDS system is context-sensitive,
EBMPracticeNet had the responsibility to tailor the dia-
betes reminders and suggestions. Diabetes reminders
were adapted to the Belgian context in collaboration
with Domus Medica, a Belgian organization delivering
evidence-based information for primary care. This adap-
tation process also included careful selection of the most
relevant messages for the Belgian family physician, tak-
ing into account the risk of alert fatigue.
The EBMeDS system in the intervention groups
The EBMeDS system receives structured patient data from
the electronic medical records in HealthOne and returns
reminders, therapeutic suggestions, and diagnosis-specific
links to guidelines. Electronic forms and calculators (e.g., acalculator for glomerular filtration) are integrated in the
system.
The original EBMeDS system covers a full spectrum of
all clinical areas. Relevant reminders in all clinical areas
are shown to the physicians in the intervention group,
but analysis is limited to the treatment and follow-up of
diabetes patients.
HealthOne is one of the electronic medical record sys-
tems in Belgium. The software enables physicians to rec-
ord patient histories and contacts, to display test results,
to access generated notes and reports, and to support
physicians in decision-making for patient care.
The evidence Linker in the control and intervention
groups
The Evidence Linker has been integrated in Belgian rou-
tine practice since 2012 and could be considered part of
the usual care process. When entering a diagnosis coded
in ICPC, relevant clinical practice guidelines are re-
trieved by the Evidence Linker and can by consulted on
the initiative of the family physician.
The Evidence Linker service is offered by the Belgian
Centre for Evidence-Based Medicine (CEBAM) and is
available to all physicians in the control group as well as
in the intervention group during study follow-up.
The content and recommendations of the diabetes
guidelines presented in the Evidence Linker are similar
to the content of the EBMeDS diabetes reminders. Dif-
ferences between the intervention and control groups
are the method of evidence delivery (‘push’ versus ‘pull’)
and the format of the recommendations (‘guideline for-
mat, long’ versus ‘reminder format, short’).
Objectives
The objective of this study is to assess the feasibility of
the use of the EBMeDS system in daily Belgian family
medicine and to study the effectiveness of EBMeDS use
in improving diabetes care according to current
evidence-based guidelines. Specific research questions
are:
1. Do family physicians use the EBMeDS system in
daily practice?
2. Does the use of the EBMeDS system by family
physicians lead to an improvement in diabetes
control compared to the control group?
3. How do family physicians perceive the reminders
included in the EBMeDS system?
Outcomes
Baseline measurements
Baseline demographic data on patient age, gender, years
since the diagnosis of diabetes, nursing home residence
(yes/no), HbA1c, cholesterol levels, and blood pressure
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experience, and native language will be requested as
well.Primary and secondary outcomes
Primary outcome is the one-year pre- to post-implementation
change inHbA1c.
Secondary outcomes are the one-year differences in
cholesterol levels and systolic and diastolic blood pres-
sure. A composite patient score and a composite process
score are calculated representing the change in diabetes
(process) control and associated cardiovascular risk [19].
The composite patient score consists of reaching the
evidence-based targets for glycated hemoglobin, blood
pressure (systolic and diastolic), and cholesterol. The
process composite score consists of meeting the
evidence-based targets of the number of blood pressure
measurements, the number of laboratory results of
HbA1c, cholesterol and micro-albuminuria, a prescrip-
tion of statin (yes/no), if high cardiovascular risk a pre-
scription of aspirin/clopidogrel (yes/no), if hypertension
or nephropathy ACE inhibition/sartan (yes/no).
Outcomes that cannot be reliably detected from the
electronic medical records such as smoking status, and
feet and eye examinations are excluded from the com-
posite scores, as well as outcomes in which family physi-
cians’ influences are minimal (e.g., BMI, physical activity,
etc.).
Outcomes of the composite scores with their respect-
ive targets are shown in Table 1. Recommendations and
targets are based on the diabetes guidelines of Domus
Medica [20] and the Belgian ‘Zorgtraject diabetes’ [21].Table 1 Variables included in the composite scores
Variable Process
target
Maximum
score per
period*
Clinical
target
Maximum
score per
period †
HbA1c Quarterly 2 < 7% 1
Blood pressure Quarterly 2 < 130/80
mm Hg
1
Cholesterol (LDL,
HDL, Total)
Annual 1 LDL <
100
mg/dL
1
Microalbuminuria check Annual 1
A prescription of statin Yes/no 1
If high cardiovascular
risk, a prescription of
aspirin/clopidogrel
Yes/no 1
If hypertension or
nephropathy, ACE
inhibition/sartan
Yes/no 1
Total 9 3
*Maximum score for process composite per period = 9 (7 variables).
† Maximum score for patient composite per period = 3 (3 variables).Each of the parameters in the composite scores is
compared with their respective target. Each outcome
that meets the target will be assigned one point. If all
outcomes meet the targets, a maximum score of 3 points
will be assigned to the patient composite score and a
maximum score of 9 points will be assigned to the
process composite score. If we cannot find any data
about the process variable, we will assume that it did not
happen. A variable that improves during the intervention
period will be scored as +1; each variable that worsens
will be scored as −1; and each variable that does not
change will be scored as 0. As such, composite scores
can be grouped into three categories: worsened, un-
changed or improved.
The follow-up period will be 12 months. Outcomes
will be collected at five points: before the start of the
study, at 3 months, at 6 months, at 9 months and at
12 months, with the differences between pre- and post-
implementation forming the outcome scores. A mean
will be calculated for the intervention and control
groups. The trial will be terminated at one of the interim
analysis points when a mean difference of 0.3% might be
reached for the primary outcome of HbA1c change.
Process evaluation
In the process evaluation, actual use of the system as
well as users’ perceptions about the feasibility of the
electronic decision support will be measured. These as-
pects are two necessary components of a process evalu-
ation [22].
Scripts are automatically triggered, and users can see
that a script is available from their main screen but have
to click to view the script content. As such, click events
can give us an indication of physicians’ interest in using
the system. A new record is inserted in the log file for
each script that is triggered. The following data of actual
use are collected in a log file at the physician level: iden-
tification code of the script; type of script that is trig-
gered and opened (Reminder, Interaction, Contra-
indication, Drugs to avoid, Indication, GuideLine Link);
script node expanded (yes/no): e.g., a long reminder dis-
plays when a short reminder is clicked; request for the
script information (yes/no).
As such, the percentage and the type of scripts that
were opened will be calculated, as well as the percentage
of scripts that were expanded and the percentage of
scripts for which the script information was requested.
Process information regarding actual use of the Evi-
dence Linker will be logged in a similar way.
Physicians’ perceptions of the reminders
Physicians get the opportunity to give their opinion
when a reminder is triggered. Physicians can choose be-
tween useful, not useful, or no advice. They can give
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to block the reminder in the future.
Data collection
Data will be automatically extracted from the EMR of
the family physician for all patients who satisfy the eligi-
bility criteria. Data will be extracted at five points in
time: before the start of the study, at 3 months, at
6 months, at 9 months, and at 12 months. All outcomes
can be reliably determined from the electronic medical
records. When a physician closes HealthOne, a reminder
will be shown to export the data. The family physician
can visualize the data and has to confirm if he agrees to
export. Modifications to this file cannot be made by the
physician.
Identification data of the patient will be manually
converted to an output code via a hashing program in-
stalled on the computer of the family physician. Data
will be sent by mail to an independent third person. This
person will be responsible for uncoupling the identifiable
data of the family physician (name and e-mail address)
from the patient data and the data related to the actual
use of the system. A meaningless code will be allocated
to the physician’s data and its corresponding patient and
use data. The coupling between these data will be exclu-
sively possessed by this person and will be used to
couple the data at the different points in time.
These coded data will be sent securely to the re-
searcher. Patient data will be sent to the researcher at
the five interim analysis points. Data concerning
EBMeDS use will be sent once to the researcher at the
end of the study period after patient data are analyzed.
Data related to system use will be used to explore pos-
sible relationships between the patient outcomes and the
actual use of the system. As there is only one file of ac-
tual use for the physicians in the intervention group, the
researcher would not be blinded if these data were sent
together with the patient data.
Sample size
Based on the data in the literature, a mean difference of
0.3% in HbA1c change could be considered clinically
significant (SD of HbA1c change 1.3%) [23-25]. To de-
tect a mean difference of 0.3% in HbA1c change at four
post-treatment occasions, with a two-sided unpaired t-
test, a 5% family-wise significance level and Bonferroni
correction for multiple testing, 1:1 allocation and a
power of 80%, a sample size of 463 patients in each
group will be necessary, assuming a withdrawal rate of
10%. Additional adjustment for clustering of patients
within physician practices by the design effect [26], as-
suming 10 patients per cluster and an intra-class correl-
ation coefficient of 0.047 based on data in the literature
[27], leads to a sample size of 659 patients in each arm.Sample size calculations were based on historical data.
They can be adjusted after baseline registrations if cor-
rect standard deviations and intra-cluster correlation
coefficients are known. Sample size calculation was
performed using SAS software.
Recruitment
All Dutch- and French-speaking family physicians who
use HealthOne in their daily practice will be informed
about the study and will be sent an e-mail invitation to
participate by one of the researchers. Physicians who do
not react to the e-mail after 14 days will be sent a re-
minder. Any physicians who do not react to the second
reminder will be telephoned by one of the researchers
after another seven days.
Randomization
Physician practices that agree to participate will be ran-
domly assigned to one of the two groups following sim-
ple randomization procedures. Randomization will be
performed by a statistical consultant with an electronic
random list generator, anonymously for the researchers.
Allocation will be concealed from the participants until
the study start and after physicians’ informed consent is
obtained. Physicians will be aware of the allocated arm;
patients will not be informed about the intervention.
Data analysts will be kept blinded to the allocation. Out-
comes are objective measures directly extracted from
the electronic medical records.
Data analysis
Descriptive statistics will be provided regarding baseline
variables of the patients and the family physicians. Inter-
vention and control groups will be compared regarding
baseline variables to evaluate the randomization. Linear
mixed models will be used for continuous patient-level
variables, with a random intercept to account for clus-
tering of patients within physician practices. Logistic re-
gression models based on generalized estimating
equations (GEE) to account for clustering will be used
for binary patient-level variables.
Differences between intervention and control groups
regarding continuous outcome measures (change versus
baseline in HbA1c, cholesterol levels, and blood pres-
sure) will be assessed using linear mixed models (multi-
level regression models) with random intercepts for
physician practices and random intercepts for patients
to account for repeated measurements over time. The
primary fixed effect of interest will be the difference be-
tween intervention and control group, which will be
tested at each time point (3 m, 6 m, 9 m and 12 m). If
important differences in baseline characteristics are
demonstrated between both groups, we will account for
that by including the relevant variables in the model.
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regarding three-level composite scores (worsening,
unchanged, improvement) will be assessed using
random-effects proportional odds models, or, in case the
proportional odds assumptions do not hold, baseline-
category logits models, with random intercepts for phys-
ician practices and random intercepts for patients to
account for repeated measurements over time. As with
the analysis of continuous outcomes, differences be-
tween intervention and control groups will be tested at
all time-points, and correction for imbalance in baseline
characteristics will be applied if indicated.
To study the effect of the actual use of the EBMeDS
system on the outcome measures, models similar to
those described above will be used for analyzing the ef-
fect of intervention. However, they will now include a
measure for the use of EBMeDS as the main explanatory
variable, and will restrict analysis to the data obtained in
the intervention group.
Ethics
Before the start of study, we will present the physicians
with an informed consent that outlines the EBMeDS
intervention and the purpose of the trial to study the ef-
fectiveness of the system.
Individual informed consent from the patient cannot
be sought. Reminders show up unexpectedly during
practice when patient data deviate from evidence-based
targets. It is not practical to ask for informed consent at
these moments. Furthermore, reminding the physician
of the informed consent forms at every consultation may
bias the study results in favor of the intervention.
Data exports will be compliant with privacy legislation.
Registration of the data processing to notify the Belgian
Privacy Commission was performed on the commission
website: www.privacycommission.be. Authorization for
the use of medical and personal data was requested from
the Sector Committee of Health.
Ethics committee approval for this study was obtained
from the University Hospitals Leuven Medical Ethics
Committee in May 2013.
Discussion
The strength of the EBMeDS system is its platform-
independent, service-oriented architecture with strong
central management. This technical and organizational
structure makes it possible to manage the evidence and
the system itself on a national scale. Furthermore, this
structure facilitates gradual integration in other Belgian
software packages and other healthcare settings.
The first steps towards an open environment of con-
tinuous system improvement are taken with this study.
End-users’ perceptions of the system will provide further
understanding of their information needs to improve thefeasibility of the system. The results of this study will be
applicable at a national level where system adaptations
should be made.
Although the EBMeDS system covers all clinical areas
of disease, analysis will be limited to diabetes outcomes.
We chose to start with the analysis of diabetes outcomes
as clear recommendations on the basis of high levels of
evidence exist for this pathology, but there is still a large
gap between recommended care and the care that pa-
tients actually receive. We opt to display relevant re-
minders in all clinical areas, not just for diabetes. Our
aim in so doing is to avoid drawing the attention of the
physician to diabetes and to attain full operationalization
of the system in a real-life situation in which all clinical
areas are covered.
We are aware that the success of the system will de-
pend on the quality of the data-coding and stable use of
the EMR. Before the start of the study, we planned to
correctly reorganize and code the medical records to
guarantee a clear picture from the start. We finally de-
cided not to proceed with the reorganization of the re-
cords as this might not reflect a real-life situation.
However, we will investigate this as a possible shortcom-
ing of the implementation process and will use this in-
formation in the evaluation of the feasibility of the
system and as a possible component of future training
initiatives.
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